aspirin has been researched along with Elevated Cholesterol in 143 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated the efficacy of combined therapy with probucol and cilostazol on endothelial function in silent lacunar cerebral infarcts (SLCI) and mild hypercholesterolemia." | 9.19 | Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study. ( Hattori, H; Ishihara, M; Nagata, M; Takase, B; Tanaka, Y, 2014) |
| "In a laboratory substudy of the PRAGUE-8 trial, the influences of nonmodifiable (age and sex) and modifiable (body mass index and tobacco smoke) factors, comorbidity (hypertension, hyperlipidemia, diabetes mellitus, and renal insufficiency) and cotherapy (statin, aspirin, and heparin), on the course of clopidogrel efficacy were investigated in 105 patients pretreated with clopidogrel >or=6 hours before coronary angiography +/- percutaneous coronary intervention." | 9.14 | Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox". ( Bilkova, D; Kala, P; Marinov, I; Motovska, Z; Petr, R; Simek, S; Widimsky, P, 2009) |
| "Fifty patients with hypercholesterolemia were randomly allocated to receive an 8-week therapeutic course of simvastatin 20 mg daily (n=25) or aspirin 100 mg daily (n=25)." | 9.10 | Enhanced interleukin-1beta in hypercholesterolemia: effects of simvastatin and low-dose aspirin. ( Basili, S; Cardarello, CM; Davi, G; Ferroni, P; Gazzaniga, PP; Martini, F, 2003) |
| "In men with hypercholesterolemia, lowering serum cholesterol level by a three-month simvastatin treatment is accompanied by a marked reduction of thrombin generation both at basal conditions in venous blood and after activation of hemostasis by microvascular injury." | 9.09 | Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. ( Gajewski, P; Góra, P; Jankowski, M; Musiał, J; Swadźba, J; Szczeklik, A; Undas, A, 1999) |
| "To evaluate the association between CDS tools and racial and sex disparities in the aspirin use, blood pressure control, cholesterol management, and smoking cessation (ABCS) care quality metrics among smaller primary care practices." | 8.31 | Differences in Use of Clinical Decision Support Tools and Implementation of Aspirin, Blood Pressure Control, Cholesterol Management, and Smoking Cessation Quality Metrics in Small Practices by Race and Sex. ( Atem, FD; Balasubramanian, BA; Marino, M; Roberts, MM; Wells, R, 2023) |
| "Beside its therapeutic role in the thrombotic vascular events, Clopidogrel confers significant protection against ischemic myocardial injury by counteracting the platelet-mediated inflammation and oxidative stress associated with HFD-C consumption in animals." | 7.96 | Clopidogrel Prophylaxis Abates Myocardial Ischemic Injury and Inhibits the Hyperlipidemia-Inflammation Loop in Hypercholestrolemic Mice. ( Korish, AA, 2020) |
| "We used a single, integrated, microsimulation model to generate comparable results for 3 services recommended by the US Preventive Services Task Force: aspirin counseling for the primary prevention of CVD and colorectal cancer, screening and treatment for lipid disorders (usually high cholesterol), and screening and treatment for hypertension." | 7.85 | Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention. ( Dehmer, SP; Flottemesch, TJ; LaFrance, AB; Maciosek, MV, 2017) |
| "The US Preventive Services Task Force recommends aspirin use for men aged 45 to 79, when the potential benefit of preventing myocardial infarctions outweighs the potential harm of gastrointestinal hemorrhage." | 7.81 | Aspirin Use for the Primary Prevention of Myocardial Infarction Among Men in North Carolina, 2013. ( Fleming, E; Perry, GS; Tchwenko, S, 2015) |
| " The other 32 rats were subjected to induction of hypercholesterolemia by high-fat diet for 3 weeks, followed by induction of AMI by subcutaneous injections of isoproterenol (85 mg/kg/day, for 2 days)." | 7.80 | Assessment of the prophylactic role of aspirin and/or clopidogrel on experimentally induced acute myocardial infarction in hypercholesterolemic rats. ( El-Hadidy, WF; Mannaa, HF; Mohamed, AR, 2014) |
| "Aspirin failure in ischemic stroke prevention may exceed functional resistance to aspirin and could be associated with a higher prevalence of lacunar stroke, comorbidities, and/or adverse interactions with other drugs." | 7.78 | Ischemic stroke in patients receiving aspirin. ( Ameriso, S; Ameriso, SF; Povedano, GP; Pujol Lereis, VA, 2012) |
| "Exploration of atherogenic diet-induced diabetes mellitus and the evaluation of antidiabetic potential of aspirin were carried out in this study." | 7.77 | The effect of aspirin on atherogenic diet-induced diabetes mellitus. ( Kumar, A; Parmar, HS; Sethi, A, 2011) |
| "A 58-year-old Caucasian male with a history of coronary heart disease and hypercholesterolemia, under treatment with acetyl-salicylate for 6 years and simvastatin for 2 months, presented to the Emergency Department of our hospital with epigastric pain and vomiting of 24-hour duration." | 7.73 | A case of acute pancreatitis possibly associated with combined salicylate and simvastatin treatment. ( Antonopoulos, S; Filioti, K; Giannoulis, G; Karamanolis, D; Kokkoris, S; Mikros, S; Protopsaltis, J, 2005) |
| "In men with hypercholesterolemia simvastatin treatment lowers serum levels of CRP and proinflammatory cytokines." | 7.71 | Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. ( Gajewski, P; Jankowski, M; Musial, J; Sydor, W; Szczeklik, A; Undas, A, 2001) |
| "Aspirin resistance was defined as having a closure time (CT) of <186 s with Col/Epi cartridges despite regular aspirin therapy." | 6.74 | Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease. ( Nisanci, Y; Oflaz, H; Pamukcu, B; Tirnaksiz, E, 2009) |
| "The Healthy Hearts in the Heartland (H3) study is part of a nationwide effort, EvidenceNOW, seeking to better understand the ability of small primary care practices to improve "ABCS" clinical quality measures: appropriate Aspirin therapy, Blood pressure control, Cholesterol management, and Smoking cessation." | 5.27 | Design of healthy hearts in the heartland (H3): A practice-randomized, comparative effectiveness study. ( Brown, T; Chung, I; Ciolino, JD; Jackson, KL; Kho, AN; Liss, DT; Murakami, L; Persell, SD; Walunas, TL, 2018) |
| "This study evaluated the efficacy of combined therapy with probucol and cilostazol on endothelial function in silent lacunar cerebral infarcts (SLCI) and mild hypercholesterolemia." | 5.19 | Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study. ( Hattori, H; Ishihara, M; Nagata, M; Takase, B; Tanaka, Y, 2014) |
| "In a laboratory substudy of the PRAGUE-8 trial, the influences of nonmodifiable (age and sex) and modifiable (body mass index and tobacco smoke) factors, comorbidity (hypertension, hyperlipidemia, diabetes mellitus, and renal insufficiency) and cotherapy (statin, aspirin, and heparin), on the course of clopidogrel efficacy were investigated in 105 patients pretreated with clopidogrel >or=6 hours before coronary angiography +/- percutaneous coronary intervention." | 5.14 | Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox". ( Bilkova, D; Kala, P; Marinov, I; Motovska, Z; Petr, R; Simek, S; Widimsky, P, 2009) |
| "The main objective of this study was to assess whether aspirin 100 mg QD can improve blood pressure (BP) control and endothelial function in subjects with arterial hypertension (AH) and hypercholesterolaemia." | 5.11 | Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects. ( London, D; Magen, E; Mishal, J; Priluk, R; Viskoper, JR; Yosefy, C, 2005) |
| "During a 1-year treatment period, simvastatin, 20 mg/d, produced a sustained reduction of approximately one quarter in low-density lipoprotein cholesterol levels, with no evidence of toxicity, and aspirin, 100 mg/d, did not substantially increase the risk for a major bleeding episode." | 5.11 | First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. ( Altmann, P; Armitage, J; Baigent, C; Baxter, A; Cairns, HS; Collins, R; Foley, RN; Frighi, V; Kourellias, K; Landray, M; Leaper, C; Ratcliffe, PJ; Rogerson, M; Scoble, JE; Tomson, CR; Warwick, G; Wheeler, DC, 2005) |
| "Fifty patients with hypercholesterolemia were randomly allocated to receive an 8-week therapeutic course of simvastatin 20 mg daily (n=25) or aspirin 100 mg daily (n=25)." | 5.10 | Enhanced interleukin-1beta in hypercholesterolemia: effects of simvastatin and low-dose aspirin. ( Basili, S; Cardarello, CM; Davi, G; Ferroni, P; Gazzaniga, PP; Martini, F, 2003) |
| "In men with hypercholesterolemia, lowering serum cholesterol level by a three-month simvastatin treatment is accompanied by a marked reduction of thrombin generation both at basal conditions in venous blood and after activation of hemostasis by microvascular injury." | 5.09 | Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. ( Gajewski, P; Góra, P; Jankowski, M; Musiał, J; Swadźba, J; Szczeklik, A; Undas, A, 1999) |
| "0001) after adjustment for age, aspirin use, smoking, physical activity, body mass index, and history of angina, hypertension, and high cholesterol." | 5.09 | Alcohol consumption and risk of coronary heart disease by diabetes status. ( Ajani, UA; Buring, JE; Gaziano, JM; Hennekens, CH; Liu, S; Lotufo, PA; Manson, JE, 2000) |
| " We used the search terms metabolic syndrome, abdominal obesity, waist circumference, insulin resistance, cardiovascular disease, prediabetes, diabetes, treatment, prevention, aspirin, hypertension, cholesterol, atherogenic dyslipidemia, lifestyle therapy, diet, and exercise." | 4.84 | A practical "ABCDE" approach to the metabolic syndrome. ( Bansal, S; Blaha, MJ; Blumenthal, RS; Defilippis, AP; Golden, SH; Rouf, R, 2008) |
| ", statins), and aspirin therapy for the primary prevention of coronary heart disease (CHD) in an elderly patient population (age >or=65 y)." | 4.82 | Primary prevention of coronary heart disease in the elderly. ( Dornbrook-Lavender, KA; Pieper, JA; Roth, MT, 2003) |
| "To evaluate the association between CDS tools and racial and sex disparities in the aspirin use, blood pressure control, cholesterol management, and smoking cessation (ABCS) care quality metrics among smaller primary care practices." | 4.31 | Differences in Use of Clinical Decision Support Tools and Implementation of Aspirin, Blood Pressure Control, Cholesterol Management, and Smoking Cessation Quality Metrics in Small Practices by Race and Sex. ( Atem, FD; Balasubramanian, BA; Marino, M; Roberts, MM; Wells, R, 2023) |
| "Beside its therapeutic role in the thrombotic vascular events, Clopidogrel confers significant protection against ischemic myocardial injury by counteracting the platelet-mediated inflammation and oxidative stress associated with HFD-C consumption in animals." | 3.96 | Clopidogrel Prophylaxis Abates Myocardial Ischemic Injury and Inhibits the Hyperlipidemia-Inflammation Loop in Hypercholestrolemic Mice. ( Korish, AA, 2020) |
| "We used a single, integrated, microsimulation model to generate comparable results for 3 services recommended by the US Preventive Services Task Force: aspirin counseling for the primary prevention of CVD and colorectal cancer, screening and treatment for lipid disorders (usually high cholesterol), and screening and treatment for hypertension." | 3.85 | Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention. ( Dehmer, SP; Flottemesch, TJ; LaFrance, AB; Maciosek, MV, 2017) |
| " The use of low doses of aspirin inhibits platelet aggregation and inflammation and prevents cardiovascular mortality." | 3.83 | Study of oxidative and inflammatory parameters in LDLr-KO mice treated with a hypercholesterolemic diet: Comparison between the use of Campomanesia xanthocarpa and acetylsalicylic acid. ( Beutler, H; Brusco, I; de Almeida, AS; de Oliveira, SM; Duarte, MM; Duarte, T; Hirsch, GE; Klafke, JZ; Nascimento, S; Parisi, MM; Pereira, RL; Porto, FG; Rubin, FH; Schmidt, A; Trevisan, G; Viecili, PR, 2016) |
| "The US Preventive Services Task Force recommends aspirin use for men aged 45 to 79, when the potential benefit of preventing myocardial infarctions outweighs the potential harm of gastrointestinal hemorrhage." | 3.81 | Aspirin Use for the Primary Prevention of Myocardial Infarction Among Men in North Carolina, 2013. ( Fleming, E; Perry, GS; Tchwenko, S, 2015) |
| " The other 32 rats were subjected to induction of hypercholesterolemia by high-fat diet for 3 weeks, followed by induction of AMI by subcutaneous injections of isoproterenol (85 mg/kg/day, for 2 days)." | 3.80 | Assessment of the prophylactic role of aspirin and/or clopidogrel on experimentally induced acute myocardial infarction in hypercholesterolemic rats. ( El-Hadidy, WF; Mannaa, HF; Mohamed, AR, 2014) |
| "Aspirin failure in ischemic stroke prevention may exceed functional resistance to aspirin and could be associated with a higher prevalence of lacunar stroke, comorbidities, and/or adverse interactions with other drugs." | 3.78 | Ischemic stroke in patients receiving aspirin. ( Ameriso, S; Ameriso, SF; Povedano, GP; Pujol Lereis, VA, 2012) |
| "Exploration of atherogenic diet-induced diabetes mellitus and the evaluation of antidiabetic potential of aspirin were carried out in this study." | 3.77 | The effect of aspirin on atherogenic diet-induced diabetes mellitus. ( Kumar, A; Parmar, HS; Sethi, A, 2011) |
| "05) of stroke with hypertension and diabetes mellitus; of myocardial infarction with hypertension, hypercholesterolemia, obesity, and smoking; and of peptic ulcer disease with aspirin, NSAIDs, and potassium." | 3.74 | Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. ( Bilker, WB; Lewis, JD; Schinnar, R; Strom, BL; Wang, X, 2007) |
| "Atherosclerosis being considered as an inflammatory disorder, the present study was undertaken to investigate the effectiveness of anti-inflammatory drugs (ibuprofen, aspirin, and celecoxib) in hypercholesterolemia." | 3.74 | Antiatherosclerotic activity of ibuprofen, a non-selective COX inhibitor--an animal study. ( Dabhi, JK; Mehta, A; Solanki, JK, 2008) |
| "Aspirin is a common preventative therapy in patients at risk for cardiovascular diseases, yet little is known about how aspirin protects the vasculature in hypercholesterolemia." | 3.74 | Roles of platelet and endothelial cell COX-1 in hypercholesterolemia-induced microvascular dysfunction. ( Granger, DN; Specian, RD; Tailor, A; Wallace, JL; Wood, KC, 2007) |
| "A 58-year-old Caucasian male with a history of coronary heart disease and hypercholesterolemia, under treatment with acetyl-salicylate for 6 years and simvastatin for 2 months, presented to the Emergency Department of our hospital with epigastric pain and vomiting of 24-hour duration." | 3.73 | A case of acute pancreatitis possibly associated with combined salicylate and simvastatin treatment. ( Antonopoulos, S; Filioti, K; Giannoulis, G; Karamanolis, D; Kokkoris, S; Mikros, S; Protopsaltis, J, 2005) |
| "In men with hypercholesterolemia simvastatin treatment lowers serum levels of CRP and proinflammatory cytokines." | 3.71 | Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. ( Gajewski, P; Jankowski, M; Musial, J; Sydor, W; Szczeklik, A; Undas, A, 2001) |
| "As platelet hyperactivity is important in atherosclerosis and smoking, we hypothesized higher levels of soluble platelet membrane glycoprotein V (gpV) in 95 patients with peripheral artery disease (PAD) and 92 with coronary artery disease (CAD) compared to 99 healthy controls, and examined the effects of aspirin and of smoking two cigarettes on soluble gpV and platelet function." | 3.71 | Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis--the influence of aspirin and cigarette smoking. ( Blann, AD; Cazenave, JP; Galajda, P; Gurney, D; Lanza, F; Lip, GY; Moog, S, 2001) |
| "108 male rabbits, aged 6 months, with experimental hypercholesterolemia and experimental abdominal aortic lesioning received different regimen of antiatherosclerotic treatment; 36 of them were treated with isradipine, a dihydropyridine calcium antagonist (0." | 3.68 | Concomitant aspirin treatment abolishes the antiatherosclerotic effects of the calcium channel blocker isradipine mediated by PGI2. ( Angelberger, P; Gerakakis, A; Keiler, A; Lupattelli, G; Pirich, C; Sinzinger, H; Virgolini, I, 1992) |
| "Aspirin resistance was defined as having a closure time (CT) of <186 s with Col/Epi cartridges despite regular aspirin therapy." | 2.74 | Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease. ( Nisanci, Y; Oflaz, H; Pamukcu, B; Tirnaksiz, E, 2009) |
| "Several studies have shown that treatment of coronary heart disease (CHD) does not meet the goals set in recommendations." | 2.73 | Age and gender biases in secondary prevention of coronary heart disease in a Finnish university hospital setting. ( Kähönen, M; Kallio, J; Kööbi, T; Lehtimäki, T; Lehtinen, R; Michou, SM; Niemelä, K; Nieminen, T; Nikus, K; Turjanmaa, V; Viik, J, 2007) |
| "After short episodes of reactive hyperemia, FMD was abolished by local infusion of the nitric oxide synthesis inhibitor N:(G)monomethyl-L-arginine (5." | 2.70 | Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. ( Cross, J; Deanfield, JE; Donald, AE; Kharbanda, RK; MacAllister, RJ; Mullen, MJ; Taylor, M; Vallance, P, 2001) |
| " Significant predictors of pharmacokinetic response included infusion dose and weight." | 2.70 | First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. ( Armstrong, PW; Becker, RC; Bovill, EG; Dyke, CK; Dzavik, V; Gardner, LH; Gerstenblith, G; Harrington, RA; Hasselblad, V; Hochman, JS; Kleiman, NS; Kunitada, S; Lincoff, AM; Robertson, TL; Shimoto, Y; Zillman, LA, 2002) |
| "Aspirin has higher side effect risks and requires a longer time to achieve benefit." | 2.52 | Primary prevention: do the very elderly require a different approach? ( Schwartz, JB, 2015) |
| "The definitions of transient ischemic attack (TIA) and stroke have evolved with advancements in medical imaging." | 2.50 | Stroke: transient ischemic attack. ( Silver, B; Wulf Silver, R, 2014) |
| "Late-onset sporadic Alzheimer's disease is a heterogeneous disorder." | 2.42 | Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. ( Casserly, I; Topol, E, 2004) |
| "Stroke is a preventable tragedy for nearly 750,000 people each year." | 2.42 | Medical prevention of stroke, 2003. ( Kirshner, HS, 2003) |
| "Current recommendations for the treatment of hypercholesterolemia include drug therapy for persons at sufficiently elevated risk for coronary heart disease." | 2.39 | Lowering risk without lowering cholesterol: implications for national cholesterol policy. ( Avins, AL; Browner, WS, 1996) |
| "Aspirin was prescribed in 99." | 1.56 | Baseline clinical characteristics and patient profile of the TURKMI registry: Results of a nation-wide acute myocardial infarction registry in Turkey. ( Akboğa, M; Aktaş, I; Aladağ, N; Arın, CB; Asoğlu, R; Deveci, OS; Doğan, A; Dural, M; Erol, MK; Güneş, Y; Ince, O; Kayıkçıoğlu, M; Kılıçkap, M; Kurt, IH; Örnek, E; Özkan, E; Şen, T; Sinan, ÜY; Somuncu, MU; Tüner, H; Yenerçağ, M; Zeybey, U, 2020) |
| "Aspirin users were found to be at increased risk for major gastrointestinal bleeding." | 1.46 | Should This Patient Receive Aspirin?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. ( Burns, RB; Graham, K; Reynolds, EE; Sawhney, MS, 2017) |
| "adults have a heart attack or stroke, resulting in approximately 30 deaths every hour and, for nonfatal events, often leading to long-term disability." | 1.40 | Million hearts: prevalence of leading cardiovascular disease risk factors--United States, 2005-2012. ( George, MG; Gillespie, C; Jamal, A; Ritchey, MD; Wall, HK, 2014) |
| "Aspirin treatment also restored endothelial function and beta(2)-adrenoceptor activity." | 1.35 | Antioxidative action of aspirin on endothelial function in hypercholesterolaemic rats. ( Fahim, M; Shahid, M; Sharma, KK; Tauseef, M, 2008) |
| "7%), all at low dosage levels." | 1.35 | [Prescription patterns for antilipidemic drugs in a group of Colombian patients]. ( Machado, JE; Mesa, G; Moncada, JC, 2008) |
| "Aspirin treatment prevented the rise in blood pressure, heart rate and significantly improved baroreflex sensitivity in hypercholesterolemic rats." | 1.34 | Aspirin restores normal baroreflex function in hypercholesterolemic rats by its antioxidative action. ( Fahim, M; Sharma, KK; Tauseef, M, 2007) |
| "Overweight and obesity are well-established risk factors for cardiovascular disease and decline in kidney function in individuals with existing chronic kidney disease (CKD)." | 1.33 | Association between body mass index and CKD in apparently healthy men. ( Buring, JE; Gaziano, JM; Gelber, RP; Kausz, AT; Kurth, T; Levey, AS; Manson, JE, 2005) |
| "The progress of leukoaraiosis is greatly inhibited by long-term correction of platelet hyper-aggregability." | 1.33 | Progress of leukoaraiosis is inhibited by correction of platelet hyper-aggregability. ( Fujita, S; Fukushima, K; Kawaguchi, T; Uehara, T, 2005) |
| "However, the treatment of hypercholesterolemia should be improved." | 1.33 | [Recording of risk factors and preventive pharmaceutical therapy among ischemic heart disease patients in family practice during the years 1993-1998]. ( Alperin, M; Goldfracht, M; Hermoni, D, 2006) |
| "During follow-up 56 recurrences occurred, making a total of 110 episodes of vitreous haemorrhage in 79 eyes of 54 patients." | 1.32 | Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease? ( Banerjee, S; Denniston, AK; Dodson, PM; Gibson, JM, 2004) |
| "Aspirin treatment reduced the development of atherosclerosis by approximately 47%." | 1.32 | Suppression of oxidative stress as a mechanism of reduction of hypercholesterolemic atherosclerosis by aspirin. ( Lee, P; Prasad, K, 2003) |
| "Unstable angina was defined as transient S-T segment changes without significant increases in CK and CK-MB." | 1.31 | Prior aspirin use in unstable angina patients with modified plasma inflammatory markers and endothelial nitric oxide synthase in neutrophils. ( de Andres, R; Farré, J; García-Méndez, A; Gómez, J; López-Farré, A; Mateos-Cáreres, PJ; Rico, L; Romero, J; Sánchez de Miguel, L, 2002) |
| "During restenosis, an impairment of nitric oxide (NO)-dependent pathways may occur." | 1.31 | Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice. ( Cirino, G; Condorelli, M; Del Soldato, P; Ignarro, LJ; Napoli, C; Pinto, A; Sica, V; Sorrentino, R, 2001) |
| "Appropriate treatment of hypercholesterolemia occurred in 96% of patients referred to a clinical pharmacy specialist, compared with 68% of those followed by primary care providers alone (p<0." | 1.31 | Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a primary care setting. ( Beckey, NP; Geber, J; Korman, L; Parra, D, 2002) |
| "The aspirin dose was 40 mg/d." | 1.30 | Both dietary fish-oil supplementation and aspirin fail to inhibit atherosclerosis in long-term vein bypass grafts in moderately hypercholesterolemic nonhuman primates. ( Almassi, GH; Boerboom, LE; Olinger, GN; Skrinska, VA, 1997) |
| " Urinary 8-epi-PGF2 alpha was unchanged after 2-week dosing with aspirin and indobufen despite complete suppression of TX metabolite excretion." | 1.30 | In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. ( Alessandrini, P; Bon, GB; Bucciarelli, T; Ciabattoni, G; Cipollone, F; Costantini, F; Davi, G; Mezzetti, A; Minotti, G; Patrono, C, 1997) |
| "Treatment with aspirin, beta blockers, and angiotensin converting enzyme inhibitors." | 1.30 | Secondary prevention in coronary heart disease: baseline survey of provision in general practice. ( Campbell, NC; Deans, HG; Rawles, JM; Ritchie, LD; Thain, J, 1998) |
| "Treatment with aspirin for 2 or 7 days had no effect on the constrictive responses at the injured site 1 month after injury or on those at the noninjured site at all times examined." | 1.29 | Inhibitory effects of aspirin on coronary hyperreactivity to autacoids after arterial balloon injury in miniature pigs. ( Ibayashi, S; Kuga, T; Ohara, Y; Shimokawa, H; Takeshita, A; Tomoike, H, 1995) |
| "The extent of carotid atherosclerosis was determined by real-time B-mode ultrasonography." | 1.29 | Risk factors for carotid atherosclerosis and platelet activation. ( Matsui, Y; Michishita, H; Shimizu, S; Sugita, M; Uyama, O, 1994) |
| "Patients with transient ischemic attacks (TIA) were previously shown to have high plasma values of thiobarbituric acid-reactive substances (TBA-RS)." | 1.28 | Blood lipid peroxides in TIA: relation to platelet function and metabolic profile. ( Alessandri, C; Balsano, F; Caliendo, C; Censi, C; Germani, M; Ghiselli, A; Servi, M; Violi, F, 1989) |
| " However, twice daily dosing with dazoxiben was effective." | 1.27 | Prolongation of platelet survival in hypercholesterolaemic rabbits by CGS 12970 (3-methyl-2-(3-pyridyl)-1 indoleoctanoic acid) and dazoxiben. ( Ambler, J; Butler, KD; Butler, PA; Shand, RA; Wallis, RB, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (7.69) | 18.7374 |
| 1990's | 35 (24.48) | 18.2507 |
| 2000's | 66 (46.15) | 29.6817 |
| 2010's | 27 (18.88) | 24.3611 |
| 2020's | 4 (2.80) | 2.80 |
| Authors | Studies |
|---|---|
| Abbasi, J | 1 |
| Roberts, MM | 1 |
| Marino, M | 1 |
| Wells, R | 1 |
| Atem, FD | 1 |
| Balasubramanian, BA | 1 |
| Korish, AA | 1 |
| Erol, MK | 1 |
| Kayıkçıoğlu, M | 1 |
| Kılıçkap, M | 1 |
| Arın, CB | 1 |
| Kurt, IH | 1 |
| Aktaş, I | 1 |
| Güneş, Y | 1 |
| Özkan, E | 1 |
| Şen, T | 1 |
| Ince, O | 1 |
| Örnek, E | 1 |
| Asoğlu, R | 1 |
| Aladağ, N | 1 |
| Zeybey, U | 1 |
| Sinan, ÜY | 1 |
| Dural, M | 1 |
| Tüner, H | 1 |
| Doğan, A | 1 |
| Yenerçağ, M | 1 |
| Akboğa, M | 1 |
| Deveci, OS | 1 |
| Somuncu, MU | 1 |
| Dehmer, SP | 1 |
| Maciosek, MV | 1 |
| LaFrance, AB | 1 |
| Flottemesch, TJ | 1 |
| Burns, RB | 1 |
| Graham, K | 1 |
| Sawhney, MS | 1 |
| Reynolds, EE | 1 |
| Shelley, D | 1 |
| Blechter, B | 1 |
| Siman, N | 1 |
| Jiang, N | 1 |
| Cleland, C | 1 |
| Ogedegbe, G | 1 |
| Williams, S | 1 |
| Wu, W | 1 |
| Rogers, E | 1 |
| Berry, C | 1 |
| Ciolino, JD | 1 |
| Jackson, KL | 1 |
| Liss, DT | 1 |
| Brown, T | 1 |
| Walunas, TL | 1 |
| Murakami, L | 1 |
| Chung, I | 1 |
| Persell, SD | 1 |
| Kho, AN | 1 |
| Ma, L | 1 |
| Waldmann, E | 1 |
| Ooi, EMM | 1 |
| Chan, DC | 1 |
| Barrett, HPR | 1 |
| Watts, GF | 1 |
| Parhofer, KG | 1 |
| Weitz, JI | 1 |
| Fazio, S | 1 |
| Li, L | 1 |
| Wang, S | 1 |
| Huang, H | 1 |
| Cai, Y | 1 |
| Xi, Y | 1 |
| Bai, Y | 1 |
| Ma, C | 1 |
| De Kam, PJ | 1 |
| Luo, WL | 1 |
| Wenning, L | 1 |
| Ratcliffe, L | 1 |
| Sisk, CM | 1 |
| Royalty, J | 1 |
| Radziszewski, W | 1 |
| Wagner, JA | 1 |
| Lai, E | 1 |
| Takase, B | 1 |
| Nagata, M | 1 |
| Hattori, H | 1 |
| Tanaka, Y | 1 |
| Ishihara, M | 1 |
| Silver, B | 1 |
| Wulf Silver, R | 1 |
| Ritchey, MD | 1 |
| Wall, HK | 1 |
| Gillespie, C | 1 |
| George, MG | 1 |
| Jamal, A | 1 |
| Mohamed, AR | 1 |
| El-Hadidy, WF | 1 |
| Mannaa, HF | 1 |
| Schwartz, JB | 1 |
| Jończyk-Skórka, K | 1 |
| Śliwczyńska-Rodziewicz, D | 1 |
| Jarmak, A | 1 |
| Kowalski, J | 1 |
| Shah, NS | 1 |
| Huffman, MD | 1 |
| Ning, H | 1 |
| Lloyd-Jones, DM | 1 |
| Nevadunsky, NS | 1 |
| Van Arsdale, A | 1 |
| Strickler, HD | 1 |
| Spoozak, LA | 1 |
| Moadel, A | 1 |
| Kaur, G | 1 |
| Girda, E | 1 |
| Goldberg, GL | 1 |
| Einstein, MH | 1 |
| Tchwenko, S | 1 |
| Fleming, E | 1 |
| Perry, GS | 1 |
| Klafke, JZ | 1 |
| Pereira, RL | 1 |
| Hirsch, GE | 1 |
| Parisi, MM | 1 |
| Porto, FG | 1 |
| de Almeida, AS | 1 |
| Rubin, FH | 1 |
| Schmidt, A | 1 |
| Beutler, H | 1 |
| Nascimento, S | 1 |
| Trevisan, G | 1 |
| Brusco, I | 1 |
| de Oliveira, SM | 1 |
| Duarte, MM | 1 |
| Duarte, T | 1 |
| Viecili, PR | 1 |
| Jomni, T | 1 |
| Bellakhal, S | 1 |
| Abouda, M | 1 |
| Abdelaali, I | 1 |
| Douggui, H | 1 |
| Matsuo, K | 1 |
| Cahoon, SS | 1 |
| Yoshihara, K | 1 |
| Shida, M | 1 |
| Kakuda, M | 1 |
| Adachi, S | 1 |
| Moeini, A | 1 |
| Machida, H | 1 |
| Garcia-Sayre, J | 1 |
| Ueda, Y | 1 |
| Enomoto, T | 1 |
| Mikami, M | 1 |
| Roman, LD | 1 |
| Sood, AK | 1 |
| Sanchez, J | 1 |
| Illnait, J | 1 |
| Mas, R | 1 |
| Mendoza, S | 1 |
| Fernandez, L | 1 |
| Mesa, M | 1 |
| Vega, H | 1 |
| Fernandez, J | 1 |
| Reyes, P | 1 |
| Ruiz, D | 1 |
| Blaha, MJ | 1 |
| Bansal, S | 1 |
| Rouf, R | 1 |
| Golden, SH | 1 |
| Blumenthal, RS | 1 |
| Defilippis, AP | 1 |
| Tauseef, M | 2 |
| Shahid, M | 1 |
| Sharma, KK | 2 |
| Fahim, M | 2 |
| Dabhi, JK | 1 |
| Solanki, JK | 1 |
| Mehta, A | 1 |
| Motovska, Z | 1 |
| Widimsky, P | 1 |
| Petr, R | 1 |
| Bilkova, D | 1 |
| Marinov, I | 1 |
| Simek, S | 1 |
| Kala, P | 1 |
| Galesic, M | 1 |
| Garcia-Retamero, R | 1 |
| Gigerenzer, G | 1 |
| Mora, S | 1 |
| Rifai, N | 1 |
| Buring, JE | 4 |
| Ridker, PM | 2 |
| Hatoum, IJ | 1 |
| Nelson, JJ | 1 |
| Cook, NR | 1 |
| Hu, FB | 1 |
| Rimm, EB | 1 |
| Sethi, A | 1 |
| Parmar, HS | 1 |
| Kumar, A | 1 |
| Luzak, B | 1 |
| Boncler, M | 1 |
| Rywaniak, J | 1 |
| Wilk, R | 1 |
| Stanczyk, L | 1 |
| Czyz, M | 1 |
| Rysz, J | 1 |
| Watala, C | 1 |
| Tchan, M | 1 |
| Sillence, D | 1 |
| Pujol Lereis, VA | 1 |
| Ameriso, S | 1 |
| Povedano, GP | 1 |
| Ameriso, SF | 1 |
| Yusuf, S | 1 |
| Pais, P | 1 |
| Sigamani, A | 1 |
| Xavier, D | 1 |
| Afzal, R | 1 |
| Gao, P | 1 |
| Teo, KK | 1 |
| Napoli, C | 2 |
| Ackah, E | 1 |
| De Nigris, F | 1 |
| Del Soldato, P | 2 |
| D'Armiento, FP | 1 |
| Crimi, E | 1 |
| Condorelli, M | 2 |
| Sessa, WC | 1 |
| Szczeklik, A | 7 |
| Musiał, J | 3 |
| Undas, A | 6 |
| Mateos-Cáreres, PJ | 1 |
| García-Méndez, A | 1 |
| Farré, J | 1 |
| Sánchez de Miguel, L | 1 |
| Gómez, J | 1 |
| de Andres, R | 1 |
| Rico, L | 1 |
| Romero, J | 1 |
| López-Farré, A | 1 |
| Prasad, K | 1 |
| Lee, P | 1 |
| Kurth, T | 2 |
| Kase, CS | 1 |
| Berger, K | 1 |
| Schaeffner, ES | 1 |
| Gaziano, JM | 3 |
| Vaur, L | 1 |
| Danchin, N | 1 |
| Hanania, G | 1 |
| Cambou, JP | 1 |
| Lablanche, JM | 1 |
| Blanchard, D | 1 |
| Clerson, P | 1 |
| Gueret, P | 1 |
| Kirshner, HS | 1 |
| Ferroni, P | 1 |
| Martini, F | 1 |
| Cardarello, CM | 1 |
| Gazzaniga, PP | 1 |
| Davi, G | 4 |
| Basili, S | 2 |
| Dornbrook-Lavender, KA | 1 |
| Pieper, JA | 1 |
| Roth, MT | 1 |
| Sacco, M | 1 |
| Pellegrini, F | 1 |
| Roncaglioni, MC | 1 |
| Avanzini, F | 1 |
| Tognoni, G | 1 |
| Nicolucci, A | 1 |
| Banerjee, S | 1 |
| Denniston, AK | 1 |
| Gibson, JM | 1 |
| Dodson, PM | 1 |
| Casserly, I | 1 |
| Topol, E | 1 |
| Lim, HS | 1 |
| Blann, AD | 2 |
| Lip, GY | 4 |
| Kim, C | 1 |
| Beckles, GL | 1 |
| Critchley, J | 1 |
| Liu, J | 1 |
| Zhao, D | 1 |
| Wei, W | 1 |
| Capewell, S | 1 |
| Hirsh, J | 1 |
| Bhatt, DL | 1 |
| Freestone, B | 1 |
| Rothwell, P | 3 |
| Sudlow, C | 3 |
| Gohlke, H | 1 |
| McLaurin, EY | 1 |
| Holliday, SL | 1 |
| Williams, P | 1 |
| Brey, RL | 1 |
| Baigent, C | 1 |
| Landray, M | 1 |
| Leaper, C | 1 |
| Altmann, P | 1 |
| Armitage, J | 1 |
| Baxter, A | 1 |
| Cairns, HS | 1 |
| Collins, R | 1 |
| Foley, RN | 1 |
| Frighi, V | 1 |
| Kourellias, K | 1 |
| Ratcliffe, PJ | 1 |
| Rogerson, M | 1 |
| Scoble, JE | 1 |
| Tomson, CR | 1 |
| Warwick, G | 1 |
| Wheeler, DC | 1 |
| Antonopoulos, S | 1 |
| Mikros, S | 1 |
| Kokkoris, S | 1 |
| Protopsaltis, J | 1 |
| Filioti, K | 1 |
| Karamanolis, D | 1 |
| Giannoulis, G | 1 |
| Schaerlig, E | 1 |
| Magen, E | 1 |
| Viskoper, JR | 1 |
| Mishal, J | 1 |
| Priluk, R | 1 |
| London, D | 1 |
| Yosefy, C | 1 |
| Sanak, M | 1 |
| Gelber, RP | 1 |
| Kausz, AT | 1 |
| Manson, JE | 3 |
| Levey, AS | 1 |
| Fujita, S | 1 |
| Kawaguchi, T | 1 |
| Uehara, T | 1 |
| Fukushima, K | 1 |
| Wepner, U | 1 |
| Shimamoto, K | 1 |
| Kawana, M | 1 |
| Lip, GH | 1 |
| Goldfracht, M | 1 |
| Alperin, M | 2 |
| Hermoni, D | 1 |
| Soares, PR | 1 |
| Hueb, WA | 1 |
| Lemos, PA | 1 |
| Lopes, N | 1 |
| Martinez, EE | 1 |
| Cesar, LA | 1 |
| Oliveira, SA | 1 |
| Ramires, JA | 1 |
| Batić-Mujanović, O | 1 |
| Zildzić, M | 1 |
| Beganlić, A | 1 |
| Khalifeh, MR | 1 |
| Redett, RJ | 1 |
| Ishii, A | 1 |
| Viñuela, F | 1 |
| Murayama, Y | 1 |
| Yuki, I | 1 |
| Nien, YL | 1 |
| Yeh, DT | 1 |
| Vinters, HV | 1 |
| Lewis, JD | 1 |
| Schinnar, R | 1 |
| Bilker, WB | 1 |
| Wang, X | 1 |
| Strom, BL | 1 |
| Blinc, A | 1 |
| Poredos, P | 1 |
| Moyad, MA | 1 |
| Merrick, GS | 1 |
| Jonas, JB | 1 |
| Michou, SM | 1 |
| Kähönen, M | 1 |
| Lehtimäki, T | 1 |
| Nikus, K | 1 |
| Viik, J | 1 |
| Niemelä, K | 1 |
| Kallio, J | 1 |
| Lehtinen, R | 1 |
| Kööbi, T | 1 |
| Turjanmaa, V | 1 |
| Nieminen, T | 1 |
| Tirnaksiz, E | 1 |
| Pamukcu, B | 1 |
| Oflaz, H | 1 |
| Nisanci, Y | 1 |
| Tailor, A | 1 |
| Wood, KC | 1 |
| Wallace, JL | 1 |
| Specian, RD | 1 |
| Granger, DN | 1 |
| Korbut, RA | 1 |
| Guzik, B | 1 |
| Adamek-Guzik, T | 1 |
| Korbut, R | 1 |
| Machado, JE | 1 |
| Moncada, JC | 1 |
| Mesa, G | 1 |
| Kornitzer, M | 1 |
| Stamler, J | 1 |
| Schoenberger, JA | 1 |
| Mann, GV | 1 |
| Weber, G | 1 |
| Bianciardi, G | 1 |
| Toti, P | 1 |
| Bronner, LL | 1 |
| Kanter, DS | 1 |
| Kuga, T | 2 |
| Ohara, Y | 2 |
| Shimokawa, H | 1 |
| Ibayashi, S | 1 |
| Tomoike, H | 2 |
| Takeshita, A | 2 |
| Fitch, LL | 1 |
| Buchwald, H | 1 |
| Matts, JP | 1 |
| Johnson, JW | 1 |
| Campos, CT | 1 |
| Long, JM | 1 |
| Uyama, O | 1 |
| Matsui, Y | 1 |
| Shimizu, S | 1 |
| Michishita, H | 1 |
| Sugita, M | 1 |
| Sandercock, PA | 1 |
| Hata, H | 1 |
| Hirakawa, Y | 1 |
| Yudkin, JS | 1 |
| Smith, MJ | 1 |
| Allen, KG | 1 |
| Norman, JF | 1 |
| Harris, MA | 1 |
| Miller, CW | 1 |
| Musial, J | 2 |
| Swadzba, J | 2 |
| Gora, PF | 1 |
| Piwowarska, W | 1 |
| Duplaga, M | 1 |
| Avins, AL | 1 |
| Browner, WS | 1 |
| Calvo, F | 1 |
| Barrabés, JA | 1 |
| García-Dorado, D | 1 |
| Gresele, P | 1 |
| Violi, F | 2 |
| Catalano, M | 1 |
| Giammarresi, C | 1 |
| Volpato, R | 1 |
| Nenci, GG | 1 |
| Ciabattoni, G | 3 |
| Patrono, C | 3 |
| Laperche, T | 1 |
| Laurian, C | 1 |
| Roudaut, R | 1 |
| Steg, PG | 1 |
| Boerboom, LE | 1 |
| Olinger, GN | 1 |
| Almassi, GH | 1 |
| Skrinska, VA | 1 |
| Alessandrini, P | 1 |
| Mezzetti, A | 1 |
| Minotti, G | 1 |
| Bucciarelli, T | 1 |
| Costantini, F | 1 |
| Cipollone, F | 1 |
| Bon, GB | 1 |
| Cushman, M | 1 |
| Stampfer, MJ | 1 |
| Tracy, RP | 1 |
| Hennekens, CH | 2 |
| Campbell, NC | 1 |
| Thain, J | 1 |
| Deans, HG | 1 |
| Ritchie, LD | 1 |
| Rawles, JM | 1 |
| Noon, JP | 1 |
| Walker, BR | 1 |
| Hand, MF | 1 |
| Webb, DJ | 1 |
| Astrup, P | 1 |
| Gyntelberg, F | 1 |
| Gajewski, P | 2 |
| Góra, P | 1 |
| Jankowski, M | 2 |
| Kearney, D | 1 |
| Fitzgerald, D | 1 |
| Pascual, J | 1 |
| Thiru, K | 1 |
| Gray, J | 1 |
| Majeed, A | 1 |
| Ristimäe, T | 1 |
| Zilmer, M | 1 |
| Zilmer, K | 1 |
| Kairane, C | 1 |
| Kullisaar, T | 1 |
| Teesalu, R | 1 |
| Ogawa, T | 1 |
| Sugidachi, A | 1 |
| Naganuma, H | 1 |
| Asai, F | 1 |
| Ajani, UA | 1 |
| Lotufo, PA | 1 |
| Liu, S | 1 |
| Ghanam, K | 1 |
| Lavagna, C | 1 |
| Burgaud, JL | 1 |
| Javellaud, J | 1 |
| Ea-Kim, L | 1 |
| Oudart, N | 1 |
| Mullen, MJ | 1 |
| Kharbanda, RK | 1 |
| Cross, J | 1 |
| Donald, AE | 1 |
| Taylor, M | 1 |
| Vallance, P | 1 |
| Deanfield, JE | 1 |
| MacAllister, RJ | 1 |
| Sydor, W | 1 |
| Cockcroft, JR | 1 |
| Wilkinson, IB | 1 |
| Yki-Järvinen, H | 1 |
| Cirino, G | 1 |
| Sorrentino, R | 1 |
| Sica, V | 1 |
| Pinto, A | 1 |
| Ignarro, LJ | 1 |
| Kalashnikova, LA | 1 |
| Nasonov, EL | 1 |
| Aleksandrova, EN | 1 |
| Kosheleva, NM | 1 |
| Reshetniak, TM | 1 |
| Salozhin, KV | 1 |
| Lanza, F | 1 |
| Galajda, P | 1 |
| Gurney, D | 1 |
| Moog, S | 1 |
| Cazenave, JP | 1 |
| Piscione, F | 1 |
| Barbato, E | 1 |
| Galasso, G | 1 |
| Chiariello, M | 1 |
| Anderson, HV | 1 |
| McNatt, J | 1 |
| Clubb, FJ | 1 |
| Herman, M | 1 |
| Maffrand, JP | 1 |
| DeClerck, F | 1 |
| Ahn, C | 1 |
| Buja, LM | 1 |
| Willerson, JT | 1 |
| Campia, U | 1 |
| Choucair, WK | 1 |
| Bryant, MB | 1 |
| Quyyumi, AA | 1 |
| Cardillo, C | 1 |
| Panza, JA | 1 |
| Dyke, CK | 1 |
| Becker, RC | 1 |
| Kleiman, NS | 1 |
| Hochman, JS | 1 |
| Bovill, EG | 1 |
| Lincoff, AM | 1 |
| Gerstenblith, G | 1 |
| Dzavik, V | 1 |
| Gardner, LH | 1 |
| Hasselblad, V | 1 |
| Zillman, LA | 1 |
| Shimoto, Y | 1 |
| Robertson, TL | 1 |
| Kunitada, S | 1 |
| Armstrong, PW | 1 |
| Harrington, RA | 1 |
| Geber, J | 1 |
| Parra, D | 1 |
| Beckey, NP | 1 |
| Korman, L | 1 |
| Faergeman, O | 1 |
| Gormsen, J | 1 |
| Meinertz, H | 1 |
| Pirich, C | 1 |
| Lupattelli, G | 1 |
| Virgolini, I | 1 |
| Keiler, A | 1 |
| Gerakakis, A | 1 |
| Angelberger, P | 1 |
| Sinzinger, H | 1 |
| Averna, M | 1 |
| Catalano, I | 1 |
| Barbagallo, C | 1 |
| Ganci, A | 1 |
| Notarbartolo, A | 1 |
| Terres, W | 1 |
| Hamm, CW | 1 |
| Ruchelka, A | 1 |
| Weilepp, A | 1 |
| Kupper, W | 1 |
| Gross, PL | 1 |
| Rand, ML | 1 |
| Barrow, DV | 1 |
| Packham, MA | 2 |
| Creager, MA | 1 |
| Cooke, JP | 1 |
| Mendelsohn, ME | 1 |
| Gallagher, SJ | 1 |
| Coleman, SM | 1 |
| Loscalzo, J | 1 |
| Dzau, VJ | 1 |
| Winocour, PD | 1 |
| Vickers, JD | 1 |
| Kinlough-Rathbone, RL | 1 |
| Mustard, JF | 1 |
| Becker, G | 1 |
| Taylor, D | 1 |
| Sarris, GE | 1 |
| Fann, JI | 1 |
| Sokoloff, MH | 1 |
| Smith, DL | 1 |
| Loveday, M | 1 |
| Kosek, JC | 1 |
| Stephens, RJ | 1 |
| Cooper, AD | 1 |
| May, K | 1 |
| Willis, AL | 1 |
| Alessandri, C | 1 |
| Ghiselli, A | 1 |
| Germani, M | 1 |
| Caliendo, C | 1 |
| Censi, C | 1 |
| Servi, M | 1 |
| Balsano, F | 1 |
| Aviram, M | 1 |
| Winterstein, G | 1 |
| Brook, JG | 1 |
| Butler, KD | 1 |
| Butler, PA | 1 |
| Shand, RA | 1 |
| Ambler, J | 1 |
| Wallis, RB | 1 |
| Monti, M | 1 |
| Campanacci, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Midwest Small Practice Care Transformation Research Alliance (MSPCTRA)[NCT02598284] | 226 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination and to Evaluate Single Dose Pharmacokinetics of MK0524A in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia[NCT01012219] | Phase 1 | 36 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women[NCT00000479] | Phase 3 | 39,876 participants (Actual) | Interventional | 1992-09-30 | Completed | ||
| Effectiveness of Polypill for Primary Prevention of Cardiovascular Disease (PolyPars): Study Design and Rationale for a Pragmatic Cluster Randomized Controlled Trial[NCT03459560] | Phase 3 | 4,415 participants (Actual) | Interventional | 2015-12-20 | Active, not recruiting | ||
| Study of Heart and Renal Protection (SHARP): The Effects of Lowering LDL-cholesterol With Simvastatin 20mg Plus Ezetimibe 10mg in Patients With Chronic Kidney Disease: a Randomized Placebo-controlled Trial[NCT00125593] | Phase 4 | 9,438 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| A Multi-center, Double-Blind Randomized, Cross-over, Active-control, Comparative Clinical Study to Evaluate the Administration Time-dependent Antihypertensive Effects of Low Dose Aspirin in Well-Controlled Hypertensive Patients (Phase IV)[NCT00386529] | Phase 4 | 191 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| [NCT00000490] | Phase 3 | 0 participants | Interventional | 1973-06-30 | Completed | ||
| [NCT00005442] | 0 participants | Observational | 1994-06-30 | Completed | |||
| THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease[NCT02719665] | 30 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| Arterial Imaging of Inflammation and Resolution After Endovascular Surgery[NCT03590769] | Phase 1 | 9 participants (Actual) | Interventional | 2017-06-01 | Completed | ||
| Regulation of Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease: A Mechanistic Approach[NCT01398943] | 60 participants (Actual) | Interventional | 2010-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Cutaneous bleeding Time (BT) on Day 8 after daily administration of laropiprant with aspirin and clopidogrel for 7 days versus BT on Day 8 after daily administration of placebo with aspirin and clopidogrel for 7 days.~The model used included treatment, period and sequence as fixed effect variables and subjects as the random effect variable.~Period 3 was not analyzed as bleeding time was not an objective for this part of the study." (NCT01012219)
Timeframe: Day 8
| Intervention | Seconds (Least Squares Mean) |
|---|---|
| Clopidogrel + Aspirin +Laropiprant | 478 |
| Clopidogrel + Aspirin | 389 |
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | participants (Number) | |
|---|---|---|
| Total invasive cancer | Cancer death | |
| Aspirin + Vitamin E | 716 | 152 |
| Aspirin Only | 722 | 132 |
| Both Placebos | 706 | 143 |
| Vitamin E Only | 721 | 156 |
(NCT00000479)
Timeframe: Average follow-up 10.1 years
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Major cardiovascular event | Stroke | Myocardial infarction | Cardiovascular death | |
| Aspirin + Vitamin E | 232 | 108 | 102 | 54 |
| Aspirin Only | 245 | 113 | 96 | 66 |
| Both Placebos | 272 | 133 | 99 | 74 |
| Vitamin E Only | 250 | 133 | 94 | 52 |
Revascularization included any arterial revascularization procedure, whether surgical or percutaneous, but excluded revascularization performed for hemodialysis vascular access (e.g. fistuloplasty) or to the donor kidney transplant artery. Revascularization included amputations for vascular disease (rather than for trauma or infection). All potential revascularization events (including angiography) were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 284 |
| Placebo | 352 |
End-stage renal disease was defined as initiation of maintenance dialysis or renal transplantation. Temporary dialysis was excluded. All potential dialysis and transplant events were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 1057 |
| Placebo | 1084 |
Major atherosclerotic events defined as non-fatal myocardial infarction or coronary death, non-hemorrhagic stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 526 |
| Placebo | 619 |
Major coronary events defined as coronary death or non-fatal myocardial infarction. Myocardial infarction adjudicated based on the presence of serial changes in cardiac biomarkers (e.g. troponin, creatine kinase), typical ECG changes and typical cardiac symptoms. If myocardial infarction was fatal and post-mortem examination findings were available, this information was also assessed. All potential coronary events were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 213 |
| Placebo | 230 |
Major vascular events defined as non-fatal myocardial infarction or cardiac death, any stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 701 |
| Placebo | 814 |
Major vascular events defined as non-fatal myocardial infarction or cardiac death, any stroke, or any arterial revascularization procedure (excluding dialysis access procedures). Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 639 |
| Placebo | 749 |
Stroke was defined as rapid onset of focal or global neurological deficit, with duration greater than 24 hours. Clinical notes and brain imaging were sought to determine the stroke etiology, and if the stroke was fatal and post-mortem examination findings were available, this information was also assessed. All potential stroke events (including transient ischemic attack and intracerebral hemorrhage) were adjudicated, using pre-specified objective criteria, by clinicians blinded to study treatment allocation and lipid levels. Numbers provided = number of patients with events. (NCT00125593)
Timeframe: Median follow-up 4.9 years
| Intervention | participants (Number) |
|---|---|
| Simvastatin Plus Ezetimibe | 131 |
| Placebo | 174 |
Brachial artery FMD induced by reactive hyperemia will be used to assess vascular endothelial function at baseline and several hours after each experimental intervention. (NCT01398943)
Timeframe: Post FMD was taken approximately 110 min after baseline
| Intervention | percentage of change in FMD (Mean) | |
|---|---|---|
| Placebo | AOC Treatment | |
| All Controls | 6.7 | 6.9 |
| All COPD Patients | 3.1 | 4.7 |
A measure of vascular stiffness at baseline and several hours after each experimental intervention. (NCT01398943)
Timeframe: Post PWV was taken approximately 90 min after baseline
| Intervention | m/sec (Mean) | |
|---|---|---|
| Placebo | AOC Treatment | |
| All Controls | 11 | 10 |
| All COPD Patients | 14 | 11 |
25 reviews available for aspirin and Elevated Cholesterol
| Article | Year |
|---|---|
Stroke: transient ischemic attack.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Clopidogrel; Diffusion Magnetic Resonance I | 2014 |
Primary prevention: do the very elderly require a different approach?
Topics: Aged, 80 and over; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Dementia; Humans; Hydr | 2015 |
A practical "ABCDE" approach to the metabolic syndrome.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diet Therapy; Early Diagnosis; Evidence-Based M | 2008 |
Medical prevention of stroke, 2003.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Diet; Female; Humans; Hyp | 2003 |
Primary prevention of coronary heart disease in the elderly.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Coronary Disease; Humans; Hypercholestero | 2003 |
Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Cholest | 2004 |
Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Comorbidity; Diabetes Mellitus; Humans; Hypercholesterolemia | 2004 |
Stroke prevention.
Topics: Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Humans; | 2003 |
[Primary prevention of cardiovascular disease].
Topics: Adult; Age Factors; Aged; Antihypertensive Agents; Aspirin; Body Mass Index; Cardiovascular Diseases | 2005 |
Stroke prevention.
Topics: Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Drug Th | 2004 |
Aspirin resistance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; | 2005 |
[Acute coronary syndrome risk management].
Topics: Angina, Unstable; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Artery Disease; Humans | 2006 |
Stroke prevention.
Topics: Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Drug Therapy, Combination; E | 2005 |
The management of patients on anticoagulants prior to cutaneous surgery: case report of a thromboembolic complication, review of the literature, and evidence-based recommendations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Damage, | 2006 |
Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Diabetic Angiopathies; Humans; Hydroxymethy | 2007 |
Primary prevention of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Contraceptives, Oral; Diabetes Complications; Diet; Estrogen Rep | 1995 |
How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects.
Topics: Adult; Aspirin; Blood Pressure; Coronary Disease; Diabetes Mellitus; England; Humans; Hypercholester | 1993 |
Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin.
Topics: Aspirin; Death, Sudden, Cardiac; Depression, Chemical; Female; Fibrinolysis; Fibrinolytic Agents; Hu | 1995 |
Lowering risk without lowering cholesterol: implications for national cholesterol policy.
Topics: Adult; Antihypertensive Agents; Aspirin; Coronary Disease; Drug Costs; Estrogen Replacement Therapy; | 1996 |
The anti-thrombotic effects of statins.
Topics: Aspirin; Blood Coagulation Factors; Cholesterol, HDL; Cholesterol, LDL; Coronary Thrombosis; Humans; | 1999 |
Heart disease in older patients.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; | 1998 |
Stroke. Preemptive strikes.
Topics: Alcohol Drinking; Aspirin; Female; Hormone Replacement Therapy; Humans; Hypercholesterolemia; Hypert | 2000 |
Multiple risk factor intervention in type 2 diabetes: an opportunity not to be missed.
Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans; Hypercho | 2001 |
[Diabetes and ischemic cardiopathy].
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Diabetic Angiopathies; Hu | 2001 |
[Primary prevention of intermittent claudication and frequently associated arteriopathies].
Topics: Adult; Aspirin; Cerebrovascular Disorders; Coronary Disease; Diet; Humans; Hypercholesterolemia; Hyp | 1987 |
27 trials available for aspirin and Elevated Cholesterol
| Article | Year |
|---|---|
Quality of Cardiovascular Disease Care in Small Urban Practices.
Topics: Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Delivery of Health Care; Guideline Adhere | 2018 |
Design of healthy hearts in the heartland (H3): A practice-randomized, comparative effectiveness study.
Topics: Adult; Aspirin; Blood Pressure Determination; Cardiovascular Diseases; Female; Health Facility Size; | 2018 |
Effects of Rosuvastatin and Aspirin on Retinal Vascular Structures in Hypercholesterolemic Patients with Low-to-Moderate Risk of Coronary Artery Disease.
Topics: Arterioles; Asian People; Aspirin; Atherosclerosis; C-Reactive Protein; Coronary Artery Disease; Fem | 2019 |
The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin.
Topics: Adult; Aged; Aspirin; Clopidogrel; Cross-Over Studies; Double-Blind Method; Drug Interactions; Dysli | 2014 |
Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Cholinergic Antagonists; Cilostazol; Drug T | 2014 |
[Long-term effect of policosanol on the functional recovery of non-cardioembolic ischemic stroke patients: a one year study].
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aspirin; Brain Damage, Chronic; Brain Ischemia; C | 2017 |
Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox".
Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Aspirin; Body Mass Index; Cell Adhesion Molecules | 2009 |
The effect of a platelet cholesterol modulation on the acetylsalicylic acid-mediated blood platelet inhibition in hypercholesterolemic patients.
Topics: Acetylation; Aspirin; Atorvastatin; Blood Platelets; Blood Proteins; Cholesterol; Drug Interactions; | 2011 |
Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
Topics: Administration, Oral; Aged; Analysis of Variance; Antihypertensive Agents; Aspirin; Atenolol; Biomar | 2012 |
Enhanced interleukin-1beta in hypercholesterolemia: effects of simvastatin and low-dose aspirin.
Topics: Adult; Aged; Aspirin; Female; Humans; Hypercholesterolemia; Interleukin-1; Male; Middle Aged; Platel | 2003 |
Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial.
Topics: Aged; Aspirin; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; | 2003 |
First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
Topics: Adult; Aged; Alanine Transaminase; Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Chronic Disea | 2005 |
Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects.
Topics: Adult; Antihypertensive Agents; Aspirin; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Brac | 2005 |
Coronary revascularization (surgical or percutaneous) decreases mortality after the first year in diabetic subjects but not in nondiabetic subjects with multivessel disease: an analysis from the Medicine, Angioplasty, or Surgery Study (MASS II).
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angioplasty, Balloon, Laser-Assis | 2006 |
Age and gender biases in secondary prevention of coronary heart disease in a Finnish university hospital setting.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Asp | 2007 |
Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Colla | 2009 |
Pharmacological trials: primary and secondary prevention of coronary heart disease.
Topics: Aspirin; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Colestipol; Coronary Disease; D | 1983 |
Controversies in cardiology. Proposed: low-dose aspirin should be taken daily after age 40 if total serum cholesterol is greater than 160.
Topics: Adult; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Epoprostenol; Humans; H | 1982 |
Effect of aspirin use on death and recurrent myocardial infarction in current and former cigarette smokers. Program on the Surgical Control of the Hyperlipidemias Group.
Topics: Aspirin; Cohort Studies; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hypercholestero | 1995 |
Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease.
Topics: Adult; Aged; Aspirin; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; | 1997 |
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In | 1998 |
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In | 1998 |
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In | 1998 |
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Arteriosclerosis; Aspirin; beta Carotene; Body Mass In | 1998 |
Impairment of forearm vasodilatation to acetylcholine in hypercholesterolemia is reversed by aspirin.
Topics: Acetylcholine; Adult; Aspirin; Cyclooxygenase Inhibitors; Female; Forearm; Humans; Hypercholesterole | 1998 |
Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia.
Topics: Adult; Aspirin; Biomarkers; Cholesterol; Drug Synergism; Drug Therapy, Combination; Fibrinopeptide A | 1999 |
Alcohol consumption and risk of coronary heart disease by diabetes status.
Topics: Alcohol Drinking; Aspirin; beta Carotene; Cardiovascular Diseases; Coronary Disease; Diabetes Mellit | 2000 |
Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia.
Topics: Acetylcholine; Adolescent; Adult; Area Under Curve; Aspirin; Autonomic Agents; Blood Flow Velocity; | 2001 |
Role of cyclooxygenase products in the regulation of vascular tone and in the endothelial vasodilator function of normal, hypertensive, and hypercholesterolemic humans.
Topics: Acetylcholine; Aspirin; Blood Flow Velocity; Brachial Artery; Cholesterol; Cholesterol, HDL; Cholest | 2002 |
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin | 2002 |
91 other studies available for aspirin and Elevated Cholesterol
| Article | Year |
|---|---|
Highlights From the American Heart Association's Scientific Sessions-ApoB as a Risk Marker, an Oral PCSK9 Inhibitor, and Aspirin and Dementia.
Topics: Administration, Oral; American Heart Association; Apolipoprotein B-100; Aspirin; Biomarkers; Dementi | 2022 |
Differences in Use of Clinical Decision Support Tools and Implementation of Aspirin, Blood Pressure Control, Cholesterol Management, and Smoking Cessation Quality Metrics in Small Practices by Race and Sex.
Topics: Aspirin; Benchmarking; Blood Pressure; Cardiovascular Diseases; Cholesterol; Cross-Sectional Studies | 2023 |
Clopidogrel Prophylaxis Abates Myocardial Ischemic Injury and Inhibits the Hyperlipidemia-Inflammation Loop in Hypercholestrolemic Mice.
Topics: Animals; Aspirin; Clopidogrel; Disease Models, Animal; Humans; Hypercholesterolemia; Hyperlipidemias | 2020 |
Baseline clinical characteristics and patient profile of the TURKMI registry: Results of a nation-wide acute myocardial infarction registry in Turkey.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin Receptor Antagonists; Angiotensin-Conver | 2020 |
Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention.
Topics: Adolescent; Adult; Aged; Aspirin; Colorectal Neoplasms; Cost-Benefit Analysis; Counseling; Ethnicity | 2017 |
Should This Patient Receive Aspirin?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Topics: Anticholesteremic Agents; Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Humans; Hyp | 2017 |
Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Aspirin; Blood Component Remov | 2019 |
Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis.
Topics: Anticholesteremic Agents; Aspirin; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Re | 2019 |
Million hearts: prevalence of leading cardiovascular disease risk factors--United States, 2005-2012.
Topics: Adolescent; Adult; Aged; Aspirin; Cardiovascular Diseases; Female; Health Promotion; Humans; Hyperch | 2014 |
Assessment of the prophylactic role of aspirin and/or clopidogrel on experimentally induced acute myocardial infarction in hypercholesterolemic rats.
Topics: Animals; Aspirin; C-Reactive Protein; Cholesterol; Clopidogrel; Creatine Kinase; Diet, High-Fat; Dru | 2014 |
[Does acetylsalicylic acid and vitamin K antagonists are risk factors of macular degeneration related with age?].
Topics: Acenocoumarol; Aged; Anticoagulants; Aspirin; Case-Control Studies; Causality; Comorbidity; Female; | 2015 |
Trends in myocardial infarction secondary prevention: The National Health and Nutrition Examination Surveys (NHANES), 1999-2012.
Topics: Aged; Aspirin; Blood Glucose; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperc | 2015 |
Association Between Statin Use and Endometrial Cancer Survival.
Topics: Adult; Aged; Aspirin; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hydroxymethylglutary | 2015 |
Aspirin Use for the Primary Prevention of Myocardial Infarction Among Men in North Carolina, 2013.
Topics: Aged; Aspirin; Behavioral Risk Factor Surveillance System; Diabetes Mellitus; Humans; Hypercholester | 2015 |
Study of oxidative and inflammatory parameters in LDLr-KO mice treated with a hypercholesterolemic diet: Comparison between the use of Campomanesia xanthocarpa and acetylsalicylic acid.
Topics: Animals; Aspirin; Atherosclerosis; Brazil; Hypercholesterolemia; Inflammation; Lipoproteins, LDL; Ma | 2016 |
[An atypical presentation of celiac disease: central retinal vein occlusion].
Topics: Adult; Anemia, Iron-Deficiency; Aspirin; Biopsy; Celiac Disease; Diet, Gluten-Free; Female; Humans; | 2015 |
Association of Low-Dose Aspirin and Survival of Women With Endometrial Cancer.
Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Comorbidity; Diabetes Mellit | 2016 |
Antioxidative action of aspirin on endothelial function in hypercholesterolaemic rats.
Topics: Animals; Antioxidants; Aorta, Thoracic; Aspirin; Cholesterol; Disease Models, Animal; Endothelium, V | 2008 |
Antiatherosclerotic activity of ibuprofen, a non-selective COX inhibitor--an animal study.
Topics: Animals; Anti-Inflammatory Agents; Antiparasitic Agents; Aspirin; Atherosclerosis; Celecoxib; Diseas | 2008 |
Using icon arrays to communicate medical risks: overcoming low numeracy.
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Aspirin; Attitude to Health; Computer Graph | 2009 |
Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women.
Topics: Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Fasting; Female; Humans; Hyperch | 2009 |
Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Age Factors; Aged; Alcohol Drinking; Antichol | 2010 |
The effect of aspirin on atherogenic diet-induced diabetes mellitus.
Topics: Adipose Tissue; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Glucose; Cholestero | 2011 |
Fabry disease and Factor V Leiden: a potent vascular risk combination.
Topics: Activated Protein C Resistance; alpha-Galactosidase; Aspirin; Atorvastatin; Coronary Stenosis; Defib | 2011 |
Ischemic stroke in patients receiving aspirin.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Argentina; Aspirin; Brain Ischemia; Chi-Square Dis | 2012 |
Chronic treatment with nitric oxide-releasing aspirin reduces plasma low-density lipoprotein oxidation and oxidative stress, arterial oxidation-specific epitopes, and atherogenesis in hypercholesterolemic mice.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Aspirin; Foam Cells; Hypercholesterolemia; Lipoproteins, | 2002 |
Reasons for resistance to aspirin in cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Coagulation; Cardiovascular Diseases; Cycloo | 2002 |
Prior aspirin use in unstable angina patients with modified plasma inflammatory markers and endothelial nitric oxide synthase in neutrophils.
Topics: Aged; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Case-Control S | 2002 |
Suppression of oxidative stress as a mechanism of reduction of hypercholesterolemic atherosclerosis by aspirin.
Topics: Animals; Aorta; Aspirin; Cholesterol; Cholesterol, Dietary; Coronary Artery Disease; Cyclooxygenase | 2003 |
Smoking and the risk of hemorrhagic stroke in men.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Aspirin; beta Carotene; Body Mass Ind | 2003 |
Management and short-term outcome of diabetic patients hospitalized for acute myocardial infarction: results of a nationwide French survey.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Body Mass Index; Diabetic Angiopathies; Female; France; | 2003 |
Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease?
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cardiovascula | 2004 |
Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention.
Topics: Aged; Aspirin; Biomarkers; Blood Coagulation; Cardiovascular Diseases; CD40 Ligand; Cohort Studies; | 2004 |
Cardiovascular disease risk reduction in the Behavioral Risk Factor Surveillance System.
Topics: Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Exercise; Feeding Behavior; Female; Healt | 2004 |
More on: aspirin resistance.
Topics: Alleles; Aspirin; Drug Resistance; Factor XIII; Fibrinolytic Agents; Genotype; Humans; Hypercholeste | 2004 |
Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999.
Topics: Adult; Aged; Antihypertensive Agents; Aspirin; Cardiovascular Agents; China; Coronary Disease; Devel | 2004 |
Predictors of cognitive dysfunction in patients with systemic lupus erythematosus.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Aspirin; Autoant | 2005 |
A case of acute pancreatitis possibly associated with combined salicylate and simvastatin treatment.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Cholangio | 2005 |
[Highlights from the American College of Cardiology Annual Scientific Session 2005: March 5-9, 2005, Orlando, Florida].
Topics: Aspirin; Cardiovascular Diseases; Cholesterol, LDL; Clopidogrel; Humans; Hypercholesterolemia; Obesi | 2005 |
Association between body mass index and CKD in apparently healthy men.
Topics: Adult; Aspirin; beta Carotene; Body Mass Index; Cardiovascular Diseases; Chronic Disease; Cohort Stu | 2005 |
Progress of leukoaraiosis is inhibited by correction of platelet hyper-aggregability.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Brain; Dementia, Va | 2005 |
[Delayed coronary heart disease diagnosis, incomplete therapy. Misunderstood women's hearts].
Topics: Aspirin; Cholesterol, LDL; Coronary Disease; Diagnosis, Differential; Female; Humans; Hypercholester | 2005 |
[Recording of risk factors and preventive pharmaceutical therapy among ischemic heart disease patients in family practice during the years 1993-1998].
Topics: Adrenergic beta-Antagonists; Aspirin; Blood Pressure; Cholesterol; Cohort Studies; Family Practice; | 2006 |
Secondary prevention of coronary heart disease in primary health care.
Topics: Adult; Aged; Aspirin; Body Mass Index; Coronary Disease; Female; Humans; Hypercholesterolemia; Hyper | 2006 |
Swine model of carotid artery atherosclerosis: experimental induction by surgical partial ligation and dietary hypercholesterolemia.
Topics: Angiography; Angioplasty, Balloon; Animals; Aspirin; Calcinosis; Carotid Arteries; Carotid Artery In | 2006 |
Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colonic Neoplasms; Databases | 2007 |
Aspirin restores normal baroreflex function in hypercholesterolemic rats by its antioxidative action.
Topics: Animals; Antioxidants; Aspirin; Baroreflex; Blood Pressure; Cholesterol; Cholesterol, Dietary; Heart | 2007 |
Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
Topics: Aspirin; Cardiovascular Diseases; Cause of Death; Drug Costs; Evidence-Based Medicine; Humans; Hydro | 2007 |
Effect of statin drugs and aspirin on open-angle glaucoma progression.
Topics: Aspirin; Disease Progression; Drug Therapy, Combination; Glaucoma, Open-Angle; Humans; Hydroxymethyl | 2007 |
Roles of platelet and endothelial cell COX-1 in hypercholesterolemia-induced microvascular dysfunction.
Topics: Animals; Aspirin; Blood Platelets; Bone Marrow Transplantation; Cardiovascular Diseases; Cell Adhesi | 2007 |
[Beneficial effects of statins and angiotensin converting enzyme inhibitors on aggregability of red blood cells in hypertensive patients].
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; | 2006 |
[Prescription patterns for antilipidemic drugs in a group of Colombian patients].
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antihypertensive Agents | 2008 |
Secondary prevention of coronary heart disease.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Disease; Diabetes Mellitus; Feeding B | 1984 |
Circulating platelets plasma-membrane of normocholesterolemic and hypercholesterolemic rabbits tested with aspirin: a freeze etching study of the platelet plasma-membrane "protuberances".
Topics: Animals; Aspirin; Blood Platelets; Cell Membrane; Cytoplasm; Diet; Freeze Etching; Hypercholesterole | 1980 |
Epidemiological feasibility of cardiovascular primary prevention in general practice: a trial of vitamin E and aspirin. Collaborative group of the Primary Prevention Project.
Topics: Aged; Arteriosclerosis; Aspirin; Cardiovascular Diseases; Clinical Protocols; Contraindications; Dia | 1995 |
Inhibitory effects of aspirin on coronary hyperreactivity to autacoids after arterial balloon injury in miniature pigs.
Topics: Angiography; Angioplasty, Balloon, Coronary; Animals; Aspirin; Autacoids; Blood Pressure; Constricti | 1995 |
Risk factors for carotid atherosclerosis and platelet activation.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Arteriosclerosis; Aspirin; Carotid Artery Diseases; Fem | 1994 |
Recent developments in secondary prevention of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Endarterectomy, Carotid; Humans; Hypercholesterolemia; Myocardia | 1993 |
Inhibitory effects of heparin, aspirin and ketanserin on coronary artery vasoconstriction after arterial balloon injury in hypercholesterolemic miniature pigs.
Topics: Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Coronary Vessels; Drug Interactio | 1993 |
Low-dose aspirin does not attenuate platelet aggregation or atherosclerosis in miniature swine but decreases production of aortic wall prostacyclin.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aorta; Arteriosclerosis; Aspirin; Azo Compounds; Coloring Age | 1995 |
Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia.
Topics: Adult; Aged; Angina Pectoris; Antithrombins; Aspirin; Cholesterol; Female; Humans; Hypercholesterole | 1996 |
[Should individuals without evidence of coronary disease and with risk factors receive continuous treatment with aspirin? Arguments in favor].
Topics: Age Factors; Aspirin; Cost-Benefit Analysis; Diabetes Complications; Female; Humans; Hypercholestero | 1996 |
Mobile thromboses of the aortic arch without aortic debris. A transesophageal echocardiographic finding associated with unexplained arterial embolism. The Filiale Echocardiographie de la Société Française de Cardiologie.
Topics: Adult; Aorta, Thoracic; Arteriosclerosis; Aspirin; Blood Coagulation Tests; Diabetes Complications; | 1997 |
Both dietary fish-oil supplementation and aspirin fail to inhibit atherosclerosis in long-term vein bypass grafts in moderately hypercholesterolemic nonhuman primates.
Topics: Animals; Arteriosclerosis; Aspirin; Coronary Artery Bypass; Dietary Fats, Unsaturated; Drug Synergis | 1997 |
In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia.
Topics: Antioxidants; Aspirin; Cardiovascular Diseases; Cross-Sectional Studies; Cyclooxygenase Inhibitors; | 1997 |
Secondary prevention in coronary heart disease: baseline survey of provision in general practice.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood P | 1998 |
[Heart magnyl or statins?].
Topics: Anticholesteremic Agents; Aspirin; Coronary Disease; Humans; Hypercholesterolemia; Risk Factors | 1998 |
Management of ischaemic heart disease in primary care: towards better practice. STaRNet. South Thames Region Network.
Topics: Adult; Aged; Anticholesteremic Agents; Aspirin; Body Mass Index; Cross-Sectional Studies; England; H | 1999 |
Effect of low-dose aspirin on the markers of oxidative stress.
Topics: Adult; Antioxidants; Aspirin; Biomarkers; Dose-Response Relationship, Drug; Humans; Hypercholesterol | 1999 |
Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs.
Topics: Adenosine Diphosphate; Administration, Oral; Alanine; Animals; Arteriovenous Shunt, Surgical; Aspiri | 2000 |
Involvement of cyclooxygenase 2 in the protective effect of 17beta-estradiol on hypercholesterolemic rabbit aorta.
Topics: Acetylcholine; Adenine; Animals; Aorta; Aspirin; Cholesterol; Cyclooxygenase 2; Cyclooxygenase 2 Inh | 2000 |
Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; C-Reactive Protei | 2001 |
Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice.
Topics: Animals; Aspirin; Constriction, Pathologic; Hypercholesterolemia; Mice; Mice, Inbred C57BL; Mice, Kn | 2001 |
[Antibodies to phospholipids and ischemic disorders of cerebral circulation in young age].
Topics: Adolescent; Adult; Age Factors; Alcohol Drinking; Antibodies, Antiphospholipid; Anticoagulants; Anti | 1997 |
Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis--the influence of aspirin and cigarette smoking.
Topics: Adenosine Diphosphate; Adult; Aged; Arteriosclerosis; Aspirin; beta-Thromboglobulin; Biomarkers; Cho | 2001 |
Platelet inhibition reduces cyclic flow variations and neointimal proliferation in normal and hypercholesterolemic-atherosclerotic canine coronary arteries.
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Coagulation; Blood Flo | 2001 |
Optimizing drug therapy in patients with cardiovascular disease: the impact of pharmacist-managed pharmacotherapy clinics in a primary care setting.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cardiovascular Disea | 2002 |
Anti-platelet drugs and portacaval anastomosis for homozygous hypercholesterolaemia.
Topics: Adolescent; Adult; Aspirin; Child; Dipyridamole; Female; Homozygote; Humans; Hypercholesterolemia; M | 1976 |
Concomitant aspirin treatment abolishes the antiatherosclerotic effects of the calcium channel blocker isradipine mediated by PGI2.
Topics: Animals; Aorta, Abdominal; Arteriosclerosis; Aspirin; Calcium Channel Blockers; Cholesterol; Dihydro | 1992 |
Increased thromboxane biosynthesis in type IIa hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Aspirin; Blood Platelets; Dose-Response Relationship, Drug; F | 1992 |
[Cardiovascular risk factors and restenosis after PTCA].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Coro | 1992 |
Platelet hypersensitivity in cholesterol-fed rabbits: enhancement of thromboxane A2-dependent and thrombin-induced, thromboxane A2-independent platelet responses.
Topics: Adenosine Diphosphate; Animals; Aspirin; Blood Platelets; Cholesterol; Collagen; Hypercholesterolemi | 1991 |
Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans.
Topics: Adult; Arm; Aspirin; Female; Humans; Hypercholesterolemia; Male; Methacholine Chloride; Methacholine | 1990 |
Thrombin-induced inositol phosphate production by platelets from rats with diet-induced or genetically determined hypercholesterolemia.
Topics: Animals; Aspirin; Blood Platelets; Cholesterol, Dietary; Creatine Kinase; Hypercholesterolemia; Inos | 1990 |
Managing lipid disorders.
Topics: Aspirin; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Hypercholesterolemia; Niaci | 1990 |
Myocardial infarction. Primary prevention.
Topics: Adult; Aspirin; Female; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial In | 1990 |
Mechanisms responsible for inhibition of vein-graft arteriosclerosis by fish oil.
Topics: Animals; Arteriosclerosis; Aspirin; Carotid Arteries; Dogs; Drug Evaluation, Preclinical; Drug Thera | 1989 |
Blood lipid peroxides in TIA: relation to platelet function and metabolic profile.
Topics: Administration, Oral; Aged; Arteriosclerosis; Aspirin; Blood Glucose; Blood Platelets; Coronary Dise | 1989 |
Differential effect of platelet inhibitors in normal and in hypercholesterolaemic subjects.
Topics: Adult; Aspirin; Cyclic AMP; Dipyridamole; Epoprostenol; Humans; Hypercholesterolemia; In Vitro Techn | 1985 |
Prolongation of platelet survival in hypercholesterolaemic rabbits by CGS 12970 (3-methyl-2-(3-pyridyl)-1 indoleoctanoic acid) and dazoxiben.
Topics: Animals; Aspirin; Blood Platelets; Cell Survival; Cholesterol, Dietary; Cyclooxygenase Inhibitors; H | 1987 |
[Current data on the physiopathological and therapeutic importance of vitamin C].
Topics: Ascorbic Acid; Ascorbic Acid Deficiency; Aspirin; Barbiturates; Common Cold; Humans; Hypercholestero | 1974 |